Latest Coronary stent Stories
Results of the FAME 2 Cost-Effectiveness Trial Presented at TCT 2012 A strategy of up-front percutaneous coronary intervention (PCI) for lesions confirmed to be obstructive by fractional flow reserve (FFR) was shown to be cost-effective in terms of quality-adjusted life years when compared to medical therapy alone. Results of the Cost-Effectiveness sub study of the FAME 2 trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium....
MIAMI, October 24, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC: NSPR) ("InspireMD" or the "Company"), announced its proprietary MGuard(TM) Embolic Protection Stent (EPS) was shown to be significantly superior when compared to standard bare metal and drug eluting stents in achieving complete ST resolution and restoring normal blood flow in a major study of 432 randomized patients undergoing emergency coronary intervention for potentially fatal heart attacks. The data was...
NATICK, Mass., Oct. 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element(TM) and PROMUS Element(TM) Plus Coronary Stent Systems to include three-month Dual Anti-Platelet Therapy (DAPT). This language outlines a minimum duration of three months of DAPT for certain patients who may need to interrupt or discontinue the medication for a variety of reasons and supports the strong safety...
DURHAM, N.C., Oct. 23, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced positive data from two clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release. Eighteen-month outcomes from the DESSOLVE I trial, and nine-month data supporting all study endpoints in the DESSOLVE II...
NATICK, Mass., Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element(TM) Everolimus-Eluting Platinum Chromium (PtCr) Stent System in patients with long coronary lesions. Results were presented today by Paul S. Teirstein, M.D., of the Scripps Clinic in La Jolla, California, and Co-Principal Investigator of the trial, at the 24th Annual...
TEL AVIV, Israel, October 22, 2012 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPR) announced updates on current commercial activities and unreviewed sales results for the period ended Sept. 30, 2012, the first quarter of its 2013 fiscal year. As previously announced, the Company changed its fiscal year to cover the period of July 1 to June 30. The Company said it renegotiated its product design licensing agreement with Svelte Medical...
NATICK, Mass., Oct. 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, which takes place October 22 - 26 in Miami, Florida. The clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and...
WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Today, the Society for Cardiovascular Angiography and Interventions (SCAI) announced results from a new survey that found four out of five (81 percent) patients say their lives have changed for the better following angioplasty, a procedure to open blocked arteries and allow blood to circulate freely. Simultaneously, SCAI published a comprehensive review of research on quality of life following angioplasty and stenting. The paper offers...
HONG KONG, Oct. 16, 2012 /PRNewswire/ -- OrbusNeich today announced that multiple presentations of clinical data for the COMBO Dual Therapy Stent will take place next week at TCT 2012 in Miami Beach. The scientific sessions will feature cumulative results from the REMEDEE study (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), a randomized trial of the COMBO Dual Therapy Stent versus a drug eluting stent, and data from the REMEDEE OCT and EGO COMBO...
DURHAM, N.C., Oct. 16, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that data from clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)) will be presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium to be held in Miami, Fla. on October 22 - 26, 2012. David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer for the...
